Lys Therapeutics Company Profile

Background

Overview

Lys Therapeutics is a French biotechnology company specializing in the development of first-in-class monoclonal antibodies aimed at treating neurovascular and neurodegenerative diseases. The company's lead candidate, LYS241, is a vascular-targeting immunotherapy designed to counteract neuroinflammation and blood-brain barrier (BBB) disruption by blocking the pathological interaction between tissue plasminogen activator (tPA) and NMDA receptors. This mechanism is central to the pathogenesis of several major neurological disorders, including Parkinson’s disease, ischemic stroke, and other neuro-inflammatory conditions.

Mission and Vision

Lys Therapeutics is committed to pioneering innovative biotherapies that address the underlying causes of neurodegenerative and neurovascular diseases, aiming to restore physiological function and improve patient outcomes.

Primary Area of Focus

The company's primary focus is on developing therapies that target neuroinflammation and BBB disruption, which are key factors in the progression of various neurological disorders.

Industry Significance

By targeting fundamental mechanisms of neurodegeneration, Lys Therapeutics seeks to fill significant unmet medical needs in the treatment of neurological diseases, offering potential breakthroughs in patient care.

Key Strategic Focus

Core Objectives

Develop and advance LYS241 through preclinical and clinical stages.

Establish strategic partnerships to enhance research capabilities and accelerate development timelines.

Secure funding to support ongoing and future clinical trials.

Specific Areas of Specialization

Neuroinflammation

Blood-brain barrier disruption

Monoclonal antibody development

Key Technologies Utilized

Monoclonal antibody technology

Targeted immunotherapy

Neuroinflammation modulation

Primary Markets or Conditions Targeted

Parkinson’s disease

Ischemic stroke

Multiple sclerosis

Financials and Funding

Total Funds Raised

As of November 2022, Lys Therapeutics secured a total of €5.5 million in funding.

Recent Funding Rounds

Seed Round (November 2022): €5.5 million, comprising €3 million in equity investment and €2.5 million in grants and loans.

Notable Investors

HTH VC

Philippe Bissay, CEO of H.A.C. Pharma

Intended Utilization of Capital

The funds are allocated for the production of the monoclonal antibody glunomab/glunozumab in compliance with Good Manufacturing Practice (GMP) and to complete regulatory preclinical studies supporting future clinical trials.

Pipeline Development

Key Pipeline Candidates

LYS241 (Glunomab/Glunozumab): A monoclonal antibody targeting neuroinflammation and BBB disruption.

Stages of Clinical Trials or Product Development

Preclinical stage, with plans to initiate clinical trials upon completion of regulatory studies.

Target Conditions

Parkinson’s disease

Ischemic stroke

Multiple sclerosis

Relevant Timelines for Anticipated Milestones

Completion of preclinical studies and initiation of clinical trials are anticipated following the successful production of glunomab/glunozumab.

Technological Platform and Innovation

Proprietary Technologies

Monoclonal antibody development targeting neuroinflammation and BBB disruption.

Significant Scientific Methods

Targeted immunotherapy to modulate neuroinflammation.

Leadership Team

Dr. Manuel Blanc

Position: Co-founder, Chief Executive Officer, and President

Professional Background: Over 15 years in preclinical and clinical project management, strategy, and business development in the biotech and pharmaceutical industries. Former manager at SANOFI and SANOFI Pasteur, Project Leader at ERYTECH Pharma, and Chief Scientific Officer & Head of Corporate Development in other startups specialized in neuroscience.

Contributions: Led the development of Lys Therapeutics' lead candidate, LYS241, and established strategic partnerships to advance the company's research initiatives.

Dr. Nathalie Deletage

Position: Senior Program Manager, Preclinical & Clinical R&D

Professional Background: Over 25 years of experience in R&D and preclinical drug development, specializing in neurosciences. Contributed to the development of first-in-class disease-modifying drugs for neurodegenerative and traumatic neurological disorders.

Contributions: Oversees preclinical and clinical research programs, ensuring alignment with the company's strategic objectives.

Dr. Jean-Baptiste Bertrand

Position: Head of Clinical & Non-Clinical Operations

Professional Background: Over 18 years in medical research, including 14 years in biotech companies. Experience in product development and management of complex scientific projects.

Contributions: Manages clinical and non-clinical operations, ensuring efficient execution of research and development activities.

Dr. Fanny Potzeha

Position: Project & Lab Manager, Preclinical R&D

Professional Background: 10 years in R&D and preclinical development, specializing in neurosciences and research project management.

Contributions: Manages and supervises multi-approach projects on neurological disorders, translational therapy, and brain development.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in the field of neurodegenerative and neurovascular diseases, is characterized by rapid innovation and significant investment. Companies are focusing on developing therapies that address the underlying causes of these diseases, with an emphasis on neuroinflammation and BBB disruption.

Competitor Analysis

Lyra Therapeutics: Focuses on anti-inflammatory therapies for chronic rhinosinusitis.

Lycia Therapeutics: Develops protein degradation drugs for cancer and autoimmune diseases.

Lykos Therapeutics: Specializes in mental health treatments using investigational psychedelics.

Strategic Collaborations and Partnerships

Inserm Transfert: Signed a three-year research agreement to support preclinical studies for LYS241.

The Michael J. Fox Foundation: Received a $5 million grant to advance immunotherapy for Parkinson’s disease.

Operational Insights

Lys Therapeutics differentiates itself through its unique approach targeting the interaction between tPA and NMDA receptors, aiming to restore BBB integrity and reduce neuroinflammation. This strategy positions the company to address significant unmet needs in the treatment of neurological disorders.

Strategic Opportunities and Future Directions

The company plans to advance LYS241 through clinical trials, leveraging strategic partnerships and funding to accelerate development. Future directions include expanding the pipeline to include additional therapeutic candidates targeting neurodegenerative and neurovascular diseases.